Bristol-Myers Squibb Company (BMY)

62.31
0.53 0.86
NYSE
Prev Close 61.78
Open 61.79
Day Low/High 61.65 / 62.31
52 Wk Low/High 45.76 / 68.34
Volume 7.84M
Exchange NYSE
Shares Outstanding 2259.75B
Market Cap 140.51B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Election Hindsight, Treasury Yields, Fed Day, Chip Stock Setup, A Great Trade

Election Hindsight, Treasury Yields, Fed Day, Chip Stock Setup, A Great Trade

The most important market takeaway right now is that both the Nasdaq Composite and S&P 500 have filled their respective gaps and retaken their 50-day simple moving averages.

Jim Cramer: Let's Bust These Election Myths

Jim Cramer: Let's Bust These Election Myths

These are the top five misconceptions about presidential elections -- and the stocks that you should look at right now.

Jim Cramer: Here's Why the President Is Gambling With Stimulus

Jim Cramer: Here's Why the President Is Gambling With Stimulus

The market is reflecting a triumph of big business over small business, and here's what that means for individual stocks.

Bristol-Myers Squibb Could Soon Break Out of a Large Triangle Pattern

Bristol-Myers Squibb Could Soon Break Out of a Large Triangle Pattern

Aggressive traders could go long BMY at two price levels.

Trump's Health and the Market, Charts That Matter, Nvidia News, URI Breaks Out

Trump's Health and the Market, Charts That Matter, Nvidia News, URI Breaks Out

Even more important than fiscal support moving forward would be the concept of Covid-19 very soon being effectively treatable for the public.

Jim Cramer: Does Everyone Out There Perceive That Everything Is a Win?

Jim Cramer: Does Everyone Out There Perceive That Everything Is a Win?

It's remarkable to see such excitement based on totally contradictory theories and themes.

Does 'Aggressive' Bristol-Myers Have the Right Prescription for Investors?

Does 'Aggressive' Bristol-Myers Have the Right Prescription for Investors?

BMY's announced acquisition of MyoKardia for $13B comes less than a year after its purchase of Celgene.

Jim Cramer: Diversification Is the Key to Getting Through This Market Upheaval

Jim Cramer: Diversification Is the Key to Getting Through This Market Upheaval

This diversification strategy lets you to capture stock market upside, while not risking your shirt.

A Healthy Dose of Vaccine and Pharmaceutical Plays

A Healthy Dose of Vaccine and Pharmaceutical Plays

6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.

Elections and Stocks: Party Performance, Predicting and Potential Market Winners

Elections and Stocks: Party Performance, Predicting and Potential Market Winners

The market's performance in the three months leading up to a presidential election has displayed an uncanny ability to forecast which party will win the White House.

Back to Back Wins for Bristol-Myers, and Here's How I'd Trade It

Back to Back Wins for Bristol-Myers, and Here's How I'd Trade It

BMY sees reason for optimism over the final half of the year.

Charting the Dow, Job Creation, Washington Deal or No Deal? Roku's Problem

Charting the Dow, Job Creation, Washington Deal or No Deal? Roku's Problem

Check out the Dow Transports and the Dow Industrials.

7 Drug Stocks With the Right Medicine for Investors

7 Drug Stocks With the Right Medicine for Investors

These pharmaceutical favorites continue to make progress on a number of fronts including a Covid-19 vaccine.

Use DRIPs to Build a Socially Responsible Portfolio

Use DRIPs to Build a Socially Responsible Portfolio

Many quality companies that fit into the socially responsible investing camp offer direct-purchase plans, allowing investors an easy way to build an SRI portfolio.

SPACs Aren't Just for Trading: 2 Attractive Buy and Hold Opportunities

SPACs Aren't Just for Trading: 2 Attractive Buy and Hold Opportunities

I like putting some of my money with incredibly successful folks who are well-connected and have a history of success.

This Chart Pattern Hints at a Bullish Future

This Chart Pattern Hints at a Bullish Future

The bullish reversal pattern is appearing not just in single names, but also in whole sectors.

Trading Volume, Late Selloffs, Peloton's Run Higher

Trading Volume, Late Selloffs, Peloton's Run Higher

As Treasury heads for longer-dated issuance and names like PTON run higher on earnings, selloffs late in the trading day continue.

Genprex Is Soaring - And There's a One Word Reason Why

Genprex Is Soaring - And There's a One Word Reason Why

The small biotech's market cap sits at $125 million, the low end of what I believe is fair.

Jim Cramer: Here Are the Stocks That 'Transom' Money Is Buying

Jim Cramer: Here Are the Stocks That 'Transom' Money Is Buying

They buy and buy and buy. The same stocks. Over and over. No end to it.

Jim Cramer: Goodbye to a Horrid Quarter

Jim Cramer: Goodbye to a Horrid Quarter

Now that the service economy is pretty much stopped in its tracks, here are promising areas, including technology as manufacturing, to consider.

Bear Markets Do End, But What Should Investors Be Doing Now?

Bear Markets Do End, But What Should Investors Be Doing Now?

At the end of the day, investors really have only three choices to make when managing an investment portfolio -- buy, hold, or sell.

Three Strategies for Income Investors

Three Strategies for Income Investors

For reliable income, a portfolio strategy generating monthly payouts, an opportunity in dividend kings, and favorites among taxable bond funds.

Watch These Biotech Names on Strong Earnings

Watch These Biotech Names on Strong Earnings

Merger activity is the number 1 driver I am watching for biotech growth.

China Reduces Tariffs, 20 Year Treasury Bonds, Pricey Peloton: Market Recon

China Reduces Tariffs, 20 Year Treasury Bonds, Pricey Peloton: Market Recon

This move by Beijing comes on top of massive injections of liquidity into that nation's financial system earlier this week.

Decisions, Decisions: AbbVie or Bristol-Myers Squibb?

Decisions, Decisions: AbbVie or Bristol-Myers Squibb?

AbbVie's weekly chart indicates its stock has room to run long term, but its daily chart suggests a rally in its shares is not imminent.

Jim Cramer: 6 Stocks to Buy on Coronavirus Fears

Jim Cramer: 6 Stocks to Buy on Coronavirus Fears

These companies all could be strong -- even if the 2019 nCoV fear spreads.